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Abstract
This paper investigates regional variations in outpatient antibiotic
use and provides a first empirical analysis based on Swiss data. We
compare Swiss antibiotic consumption with antibiotic use in other Eu-
ropean countries and present descriptive statistics at cantonal level.
Preliminary findings show that Switzerland exhibits relatively low lev-
els of consumption. There are significant diﬀerences among cantons
both in the per capita antibiotic sales and Defined Daily Doses per
1000 inhabitants per day (DID). Regression analysis suggests that
demographic factors, density of pharmacies and medical practices, in-
come and the incidence of infections are significantly related to antibi-
otic consumption.
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1 Introduction
The consumption of antibiotics has rapidly increased during the past 50 years.
Antibiotics have significantly contributed to the reduction in the likelihood of
dying from infectious diseases worldwide (WHO, 2000; 2001). However, re-
searchers suggest that almost one third of drug prescriptions are questionable
(Wise et al., 1998; Homer et al., 2000).
During the 90s, the USA experienced an increase in the use of broad spec-
trum antibiotics and prescriptions of antibiotics for common viral diseases
such as upper respiratory tract infections (Steinman et al., 2003). McCaig et
al. (2003) reports that total antibiotic prescriptions in ambulatory care fell
to 126 millions in 2000 from 151 millions in 1992. This means that 45% of the
population received antibiotics in 2000. According to Cantrell et al (2002)
antibiotic prescription rates for people with colds, URIs, and acute bronchi-
tis was 46%, 47%, and 60% in 1996. Their analysis shows that around 11
millions of prescriptions in the USA are inappropriate and estimate a waste
of health care resources up to $ 281 millions.
Antibiotic consumption may not be optimal because of multiple market
imperfections. First, patients may not face the marginal cost of drugs when
making their consumption choices. Consumers have an incentive to pur-
chase more drugs than they would if insurance was not available (Newhouse,
1993). Second, the individual production function of health is characterized
by uncertainty. Although antibiotics are not eﬀective in treatments of viral
diseases, patients’ lack of knowledge and experience may increase inappro-
priate consumption. Indeed, studies have shown that doctors decisions to
prescribe antimicrobials are related to patients’ expectations. Under time
pressure, doctors tend to satisfy their patients and to avoid follow up visits
(Butler et al., 1998). Third, marginal social benefits from consumption may
not reflect marginal private benefits. Marginal private benefits from con-
sumption may not internalize external benefits derived from one’s treatment
with antibiotics which reduces the probability of infection spreading to other
individuals (Elbasha, 2003). Finally, over consumption of antibiotics may
contribute to the selection of resistant bacteria, and hence, reduce their ef-
fectiveness (McGowan, 2001). Marginal social costs of antibiotic usage may
then not reflect marginal private costs since the latter do not consider the
costs of reduced antibiotic eﬀectiveness due to bacterial resistance (Levy,
1998 ; Coast et al., 1998). Because of resistance, antibiotics become a scarce
resource and it is in the interest of the society as a whole to preserve their ef-
fectiveness (Laxminarayan andWeitzman, 2002; Rowthorn and Brown, 2003;
Rudholm, 2002).
The investigation of regional variations in antibiotic consumption may
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contribute to the debate on appropriate antibiotic use by improving the un-
derstanding of its determinants. Moreover, the analysis may help to define
more eﬀective health care policies to reduce the resistance phenomenon.
Diﬀerences between geographical areas may be explained by demographic,
cultural, and socioeconomic factors. However, it is hard to believe that physi-
cians and/or patients in diﬀerent areas will not vary in their preferred treat-
ment practices for health conditions where alternative treatments are avail-
able and where the nature of the infection exhibits substantial uncertainty.
Researchers suggest that the investigation of small geographical areas may
bring out the role of health care supply organizational factors compared to
demand variables.
The literature lacks empirical investigation of within country variations
in antibiotic consumption. Moreover, studies focusing on international com-
parisons between countries use a descriptive statistics approach rather then
applying econometric techniques to explain the determinants of cross-country
variations (Bremon et al. 2000).
The paper intends to investigate regional variations in outpatient antibi-
otic use in Switzerland, to estimate the cantonal demand for antibiotics and
study the impact of critical factors. In section 2 we compare outpatient
antibiotic consumption in Switzerland with other European countries and
investigate cantonal diﬀerences within the country. In section 3 we estimate
the cantonal demand for outpatient antibiotics and discuss its determinants.
Section 4 concludes.
2 Variations in antibiotic consumption
2.1 Outpatient antibiotic consumption across countries
Large diﬀerences in outpatient antibiotic consumption can be observed across
European countries. Table 1 is constructed by collecting data from previous
studies (Cars et al., 2001; Cizman, 2003; Bergan, 2001; Elseviers et al.,
2003) and reports antibiotic use in 24 European countries. Relatively high
daily doses are registered for France, Spain, Portugal, Slovak Republic, and
Belgium. On the contrary, the Netherlands, Russia, Denmark, Sweden and
Germany exhibit significantly lower values.
Cars et al. (2001) analyse a range of five years, from 1992 to 1997, and
notice that substantial diﬀerences are also confirmed by trends in antibiotic
use. Italy and Luxemburg show increasing levels of antibiotic use, whereas
other countries, such as Sweden, register a reduction.
Besides diﬀerences in total consumption, there is also a large variation
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Countries 1998 2001 Countries 1998 2001
Austria 13.80 12.5 Italy 23.99 26.8
Belgium 26.72 24.5 Luxemburg 25.58 26.5
Croatia NA 17.6 Norway 14.50* 15.7
Czech Republic 19.96* 17.9 Portugal 28.83 24.6
Denmark 11.35 13 Poland NA 24.7
Finland 19.34 20 Russia 11.20* NA
France 36.51 33 Slovak Republic 28.75* 24.45
Germany 13.58 13 Slovenia 17.57 17.5
Greece 22.69 29.6 Spain 32.44 18
Holland 8.96 9 Sweden 13.51 16
Hungary 21.10* 19 UK 18.04 14.4
Ireland 18.34 NA Switzerland NA 9.46
*: Total use including hosp ita l use; NA : data not availab le.
Table 1: Outpatient antibiotic sales in DDD/1000 inhabitants (DID).
in the structure of consumption, i.e. the proportion of diﬀerent classes of
antibiotics. Broad spectrum penicillin is the most commonly used antibiotic
in 11 countries but there are significant diﬀerences in the volume of Defined
Daily Doses per 1000 inhabitants (DID) among these countries. The aver-
age daily dose is 18.97 in France compared to 2.90 in the Netherlands. In
Denmark and Sweden the most common antibiotics are narrow spectrum
penicillins. On the other side, Finland and Germany use tetracyclines more
frequently. It is worth noticing that the larger amounts of antibiotics are
associated to specific classes. Countries with higher antibiotic consumption
such as France, Spain and Italy, prescribe large amounts of quinolones and
macrolides. Focusing on Nordic countries, Bergan (2001) found that narrow
spectrum penicillins represent 20% of DID in Iceland. Phenoxymethyl and
benzylpenicillin represent 55% of the Swedish consumption and 40% of the
Danish and the Nordish consumption. The use of cephalosporins ranges from
1% in Denmark to 15% in Finland. Finally, floroquinolones are largely used
in Sweden only.
Unfortunately, no comparisons between North America and Europe are
available in terms of DID or sales per capita. USA and Canadian institutions
display data on antibiotic consumption in terms of number of prescriptions
(per 1000 inhabitants) but this figure lacks a common denominator (the
WHO standard DDD) for an international comparison. Therefore, antibi-
otic consumption can only be analysed within each country. The Canadian
Department of Health (2003) displays the number of oral antibiotic prescrip-
tions by retail pharmacies per 1000 inhabitants per year by the Anatomical
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Classification (ATC). In 2001 (2000), total outpatient antibiotic prescriptions
were around 619 (642) per 1,000 inhabitants. Broad spectrum penicillins ac-
counted for 32.5% (33%) of the total. Cephalosporins followed with 15.5%
(16%), quinolones with 13% (12%), macrolides with 24.5% (24%) and tetra-
cyclines with 6.5% (7%). The remaining 8% (8%) included sulfonamides and
other minor classes.
With respect to geographical diﬀerences, comparisons can be done across
9 Canadian regions: Alerta, British Columbia, New Brunswick, Manotoba,
Nova Scotia, Ontario, PEI and Newfoundland and Labrador, Québec, and
Saskatchwan. Wide variations are observed in terms of prescriptions for
penicillins (135 to 392 in 2001, and 150 to 400 in 2000), cephalosporins (78
to 147 in 2001, and 80 to 150 in 2000) and quinolones (50 to 110 in 2001, and
40 to 100 in 2000). On the other side, no significant diﬀerences are observed
in the proportion of macrolides.
2.2 Outpatient antibiotic consumption in Switzerland
In this section, we compare outpatient antibiotics consumption in Switzer-
land with consumption on other European countries calculated by the Eu-
ropean Surveillance of Antimocrobial Consumption (ESAC) project. This
is the first European comparison including Switzerland. We consider con-
sumption both in terms of total daily doses and their structure according to
classes of antibiotics. Swiss data were provided by IHA-IMS Health Market
Research. Since the dataset did not include Defined Daily Doses per 1000
inhabitants per day nor sales per capita, we calculated these latter measures
from provided counting units and total sales and using additional demo-
graphic information and WHO standard doses (we refer the reader to section
3.2 for further details on data).
Average consumption of antibiotics in ambulatory care is approximately
19 DID (figure 1). It is worth noticing that Swiss data refer to 2002 instead
of 2001. This may slightly bias upward the Swiss consumption. As shown
by Elseviers et al. (2003), there is a wide variation in consumption patterns
between diﬀerent European countries. The greatest consumption (32 DID) is
attained by France (FR). Switzerland exhibits relatively low volumes of an-
tibiotics use (8.97 DID). Only the Netherlands use lower volumes. This rank-
ing, apparently surprising, is in accordance with the 2001 OECD statistics
suggesting that Switzerland is among countries with low consumption rates of
pharmaceuticals. One possible explanation may be found in the organisation
of the health care system based upon private health insurances and physi-
cians’ attitude towards drugs prescription. The combination of deductibles
and direct payments may contribute to the prevention of moral hazard be-
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Figure 1: Total antibiotic use per country (2001)
haviour. Swiss physicians and patients may either be more informed about
the implications of antibiotics or face tighter financial incentives. The health
economics literature suggests that pure fee-for-service payment schemes, akin
to the Swiss one, may increase the volume of services provided compared to
capitation regimes. However, the incentive to reduce workload by increasing
prescriptions may be lower (see Scott, 2000).
When looking at the consumption structure, we observe a wide variation
in the proportion of diﬀerent classes of antibiotics between countries (figure
2). Compared to others countries, the Swiss share of quinolones is twice
as bigger as the European average. This also implies that Switzerland uses
relatively lower proportions of others classes of antibiotics.
The ranking of Switzerland between European countries in terms of per
capita consumption for diﬀerent classes of antibiotics can vary. Switzerland is
between the United Kingdom (UK) and the Slovenia (SI) for cephalosporins,
and comparable to the Netherlands for macrolides. On the other side, the
consumption of quinolones is relatively higher and Switzerland locates be-
tween Greece (GR) and Slovakia (SK).
Switzerland is similar to Austria in terms of consumption structure. Ex-
cept for the macrolides and the quinolones, the proportion of penicillins,
cephalosporins, tetracyclines and sulfonamides are the same. The propor-
tion of macrolides is higher in Austria, whereas the opposite holds for the
quinolones.
The comparison of Swiss consumption data with those from other Euro-
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Figure 2: Structure of outpatient antibiotic consumption per country
pean countries derived from the ESAC project requires additional comments.
There may be diﬀerences related to the collection of data. For instance, an-
tibiotic consumption may be underestimated since nursing homes expendi-
ture is excluded, whereas it is included in the total consumption of other
countries (for instance France and Belgium). Another source of bias can be
related to standard daily doses for children. Standard daily doses are cal-
culated for adults and daily doses for children are approximately half of the
adults’ ones. Some countries, such as Germany, distinguish between doses
for children and adults.
2.3 Cantonal diﬀerences
Switzerland is a federal state made of 26 cantons. Cantons generally diﬀer
not only with respect to geographical characteristics, but also for cultural and
socio-economic aspects of the population and the organisation of the health
care system. The analysis of cantonal diﬀerences in antibiotic consumption
may then reflect these aspects besides epidemiological ones. We investigate
cantonal antibiotic use in terms of sales per capita and DID using yearly data
in 2002 and 2003.
The average cantonal expenditure in 2002 is around CHF 12 per capita
with a standard deviation of 3.72. The expenditure varies from a minimum of
CHF 6.44 to a maximum of CHF 22.63. Diﬀerences between cantons appear
to be significantly large. The figures show that the per capita expenditure
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Figure 3: Total antibiotic use per canton
increases between 2002 and 2003 by 3.3% (figure 3).
In terms of Defined Daily Doses per 1000 inhabitants, the average can-
tonal consumption is 8.9 DID in 2002 (9.6 in 2003). The variation coeﬃcient1
is 30 in 2002 (27 in 2003). Note the wide variation between cantons. Given a
minimum cantonal consumption of 4.8 DID in 2002 (5.5 in 2003), the highest
consumption is more than 3 times greater. The median value is 8 DID in
2002 (8.9 in 2003).
Cantonal diﬀerences appear to be substantial both in 2002 and 2003.
However, the variation coeﬃcient indicates weaker cantonal variation in 2003
than in 2002. For most cantons (with the exception of Zurich and Obwalden)
consumption per capita has increased. The average increase is 7% , although
cantons such as St Gallen (SG) and Graubuden (GR) exhibit more substan-
tial growth. The t-test on the mean equality between 2002 and 2003 confirms
that consumption has significantly increased.
Looking more carefully at figure 3, we note that cantons with the highest
consumption (such as Geneva, Vaud and Valais) are generally located in
the South-West part of Switzerland. Conversely, cantons with the lowest
consumption are located North-East in the country.
Total antibiotic consumption can be disaggregated by the ATC classes
(figure 4). We summarize the following 6 main categories: penicillins, cepha-
1The variation coeﬃcient is the ratio between the standard deviation and the mean
multiplied by 100.
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Figure 4: Structure of outpatient antibiotic use in Switzerland
losporins, tetracyclines, macrolides, quinolones, and sulfonamides. Penicillins
account for 43% of total use. Quinolones follow with one fifth of the total.
Sightly below are the macrolides (16%). Cephalosporins, tetracyclines and
sulfonamides account for the remaining 21%.
Substantial local diﬀerences in terms of the proportion of each antibiotic
class on total consumption may be related to the prevalence of infections, pa-
tients‘ and doctors‘ preferences, pharmaceutical marketing strategies, health
care regulation, and the incidence of bacterial resistance. At the cantonal
level, we observe some variations in the structure of total consumption (figure
5). The proportion of penicillins is between a minimum of 36% in Obwald
(OW) and a maximum of 48% in Soleure (SO). Macrolides range from 12.3%
to 21.6% whereas quinolones vary from 17% to 23%. At first sight these
figures do not suggest any significant variation in the cantonal consumption
structure.
3 Explaining variations
Regional variations in antibiotic consumption may be explained by a va-
riety of factors. Several authors have suggested that doctors’ decision to
prescribe and patients’ use of antibiotics are explained not only by clinical
factors and by diﬀerences in bacterial infections across regions. Diﬀerence in
bacterial infection can hardly explain variation in morbidity as large as four
9
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Figure 5: Antibiotics share per canton
fold among industrialized countries. The literature has suggested the lack of
education, physicians and patients’ expectations, uncertainty, cultural and
social behaviour, and diﬀerences in regulatory practice, among other factors
(Belongia and Schwatz, 1998; Finch et al. 2004).
Previous studies focusing on the determinats of antibiotic consumption
have been conducted either in the form of trials or questionnaire surveys.
Mecfarlane et al. (2002) investigated the impact of patient’s information.
Their experiment showed that the distribution of information leaflets to pa-
tients not in need for antimicrobials eﬀectively reduced their use without
aﬀecting the doctor-patient relationship. Using a questionnaire survey on
22 Australian non-randomly selected general practitioners and 336 patients,
Cockburn and Pit (1997) showed that patients expecting a medication were
nearly three times more likely to receive it compared to other patients. More-
over, patients were ten times more likely to receive a medication if practi-
tioners perceived a patient’s expectation on prescribing. Doctors’ perception
and patients’ expectations were significantly associated to each other. Webb
and Lloyd (1994) suggested that older people are more likely to be prescribed
a medication, although this result is not confirmed by Cockburn and Pit’s
study. Harbarth et al. (2002) suggested that large diﬀerences in antibiotic
consumption between France and Germany are at least partially explained by
diﬀerences in the concentration of child care facilities and the use of breast
feeding between the two countries. Finally, Unsworth and Walley (2001)
showed that antibiotic prescribing is related to practice characteristics in the
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British NHS. Deprived and single-handed practices tend to prescribe more
but cheap antibiotics, while dispensers and trainers, with low level of depri-
vation and early wave fundholders have lower rate of prescriptions.
One alternative approach to investigate the determinants of antibiotic
consumption is to use regional consumption data and regress them against a
set of variables suggested by the literature as plausible causal factors of the
demand for drugs. We apply this approach to regional outpatient antibiotic
consumption in Switzerland and discuss it in the following section.
3.1 An econometric approach
From the economic point of view, antibiotics are an input of the health
care and the health production process. Therefore, following the Grossman’s
tradition it is possible to derive the demand for antibiotics directly from the
demand for health care. In this framework, the demand for antibiotics is a
demand derived from the demand for healthy days and can be specified using
the basic framework of household production theory2. In this framework, a
household combines drugs, health care, time, exercise, education and capital
equipment to produce healthy days.
Inspired by this approach and given the restriction of aggregate data, it
is possible to specify an ad-hoc demand function for the cantonal per capita
outpatient antibiotic consumption, where the demand for antibiotics depends
on the individual’s stock of health care (H), income (Y ), prices of antibiotics
and prices of other health care services, the incidence of infectious diseases
and other socioeconomic variables such as age, nationality and education.3
These socioeconomic variables are usually included in the model as proxies for
the individual stock of health care, which is diﬃcult to measure. Moreover,
under a pure fee-for-service reimbursement scheme, there may be incentives
to induce the demand for physicians’ services4. Thus, the demand for an-
tibiotics could also depend on some characteristics of the supply of health
care services as physicians’ density. Unfortunately, disaggregate data are not
available.
Taking into account the availability and the quality of data for the Swiss
cantons, we specify the following parsimonious empirical model for the per
2For a precise presentation of the household production theory, see Becker (1975). See
also Grossman (1972) for an application of household production theory to health care.
3Of course, we are aware that the use of aggregated data to explain individual antibi-
otics consumption implies the assumption that the hypothesized relationship between the
economic variables in question is homogeneous across all individuals. Therefore, using this
aggregate date set at the cantonal level we could encounter an aggregation bias.
4For a summary reading of the supply-induced demand theory see McGuire (2000).
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capita demand of outpatient antibiotics:
Dit = f(Yit, Pit,Dphit, Dphait, over65it, under20it, FOit, EDUit, (1)
INF1it, INF2it,DTt),
where Dit is the per capita antibiotic consumption in canton i and quarter t,
measured in Defined Daily Doses, Yit is the cantonal per capita income, Pit is
the price of a Defined Daily Dose, Dphit is the cantonal physicians’ density,
Dphait is the cantonal pharmacies’ density, over65it indicates the percentage
of the population older than 65, under20it is the percentage of the population
below 20, FOit is the share of foreigners on total population and EDit is the
percentage of individuals without post-mandatory education. Two indicators
of infections are also included in equation (1): the number of campylobacter
infections (per 100,000 inhabitants per year) and the number of streptococcus
pneumonie infections (INF1it, INF2it). Finally, DTt is a dummy variable to
control for seasonal eﬀects of antibiotic consumption. This takes value equal
to 1 for season t (t = 1, 2, 3, 4); otherwise is 0.
Estimation of equation (1) requires the specification of a functional form.
The log-log form oﬀers an appropriate functional form for answering ques-
tions about antibiotic consumption elasticities. The major advantage is that
the estimated coeﬃcients amount to elasticities, which are, therefore, as-
sumed to be constant. By applying the log-log functional form, the model
can be written as:
lnDit = β0 + β1 lnYit + β2 lnPit + β3 lnDphit + β4 lnDphait (2)
+β5 lnunder20it + β6 ln over65it + β7 lnFOit + β8 lnEDUit
+β9 ln INF1it + β10 ln INF2it + β11DT1 + β12DT2 + β13DT3 + εit.
As to the choice of the econometric technique, it should be noted that
in the econometric literature we find various types of models focusing on
cross-sectional variations, i.e. heterogeneity across units. The four most
widely used approaches are: the OLS model, the least squares dummy vari-
able (LSDV) model, the error components model (EC) and the Kmenta
approach5. Moreover, we should consider that our panel data set is char-
acterized by a relatively small number of time periods, a limited number
of cross-sectional units and a zero within variation for most of the explana-
tory variables. The only two variables that are changing over time are the
5For a detailed presentation of the econometric methods that have been used to analyse
panel data, see Greene (2003).
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outpatient per capita consumption and the price of an antibiotic daily dose.
Hence LSDV and EC models are the less appropriate ones. The estimation
of equation (2) was carried out using OLS and GLS estimation procedures
for pooled time-series and cross-sectional data suggested by Kmenta (1986)6.
Since many explanatory variables are repeated over time, we might have prob-
lems with the estimation of the variance of the coeﬃcients. For this reason we
estimated the model by OLS using the linearization/Huber/White/sandwich
(robust) estimates of variance. The correlation within cantons was also taken
into account by clustering the error as suggested by Roger (1993).
3.2 The data
The data for the estimation of equation (2) were obtained from three sources.
Information on the per capita income, physicians’ and pharmacies’ density,
demographic structure of the population, the share of foreign people, and
the level of education, were extracted from yearly publications by the Swiss
Federal Statistical Oﬃce. Information on the number of streptococcus pneu-
monie infections were obtained from the Swiss Federal Oﬃce of Public Health,
whereas the data on antibiotic consumption and price were obtained from
a data set created by IHA-IMS Health Market Research. The latter in-
cludes aggregate outpatient antibiotic expenditure and consumption of dif-
ferent classes of antibiotics for Switzerland. Quarterly data were available
for two years (2002 and 2003) and detailed at cantonal level. Five small can-
tons have been aggregated to obtain two "macro" cantons so that the total
number of cantons was reduced to 23 instead of 26.
Data on antibiotic consumption derives from transactions between whole-
salers and pharmacies and physicians in Switzerland. Since the retailers’
stock of drugs is roughly constant over time, wholesales data provide a good
estimation of outpatient antibiotic consumption in the country. However,
our data may slighly underestimate final consumption for three main rea-
sons. First, data collected correspond to ambulatory care and exclude all
drugs delivered in nursing home facilities7. Second, errors in data collection
measurements may account for approximately 5% of the data which are miss-
ing. Third, since the aim of our analysis is to focus on ambulatory care, few
antibiotic classes mainly related to hospital care (representing less than 2%
of the data) were excluded from the purchased dataset.
6For a general presentation of this econometric procedure see Kmenta (1986) and
Greene (2003). The estimation has been performed using the econometric software
“Limdep8”.
7In Switzerland around 50% of nursing homes have an internal pharmacy unit.
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The data were available on a specific software, “ORACLE sales Analyser”,
having a multidimensional cube structure: the product, the region, the time
period, the channel of sales, and measures of consumption. The dataset was
partially exported into MS Excel, LIMDEP and STATA8 formats to perform
the analysis.
The Anatomical Classification (AC-system) provided by the European
Pharmaceutical Market Research Association (EphMRA) classifies drugs into
16 groups at three or four levels with an alpha-numeric coding structure. All
anti-bacterial agents (antibiotics) are identified by the alpha-numeric code
J01. Antibiotics were disaggregated into diﬀerent classes (for example, J01F
macrolides) to investigate the consumption structure in section 2. Because
the classification system of EphMRA does not perfectly match the interna-
tional one, we rearranged some of the classes to obtain the standard antibiotic
classes commonly used in international studies8. In particular, according to
the EphMRA classification, broad spectrum penicillins (coded J01C) and
medium and narrow spectrum penicillins (coded J01H) define two separate
groups but have been groupped together in the ATC classification (J01 C
penicillins). Quinolones are included in class M in the ATC international
classification, whereas they fill class G for EphMRA. We finally summa-
rized seven diﬀerent classes : J01 A tetracyclines, J01 C penicillins, J01 D
cephalosporins, J01 F macrolides, J01 M quinolones, J01 E sulfonamides and
others.
Consumption is measured in terms of currency units (CHF) and the num-
ber of sold packages. Furthermore, the dataset provides a third measure
named Counting Units (CU). CU are defined in terms of milligrams and
days of treatment (DOT). DOT are derived from milligrams using the total
number of sold packages, the milligrams per package and the Defined Daily
Dosage (DDD) as DOT = (Number of packages)(mmg per package)/DDD.
The latter measure, according to the WHO9, is the assumed average main-
tenance dose per day for a drug used for its main indication in (by) adults.
For some products like Penicillins, the standard counting unit is not the
milligrams but the International Unit (IU) established by the UK National
Institute for Medical Research. Hence, we adapted the above expression to
8The ATC classification used in international studies is an extension of the EphMRA
classification suggested by Norwegian researchers in the 70’s. Since 1996, the use of the
ATC and, more generally, of the ATC/DDD system is recognized by the WHO as the
international standard.
9This is a constant for each active pharmaceutical ingredient. As the WHO emphasized,
the DDD is a unit of measurement and does not necessarily reflect the recommended or
the prescribed daily dose". For example, doses may depend on individual characteristics
such as age and weight.
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consider IU instead of milligrams.
In addition to the original variables we calculated total per capita sales
and days of treatment per 1000 inhabitants per day (DID) using demographic
data at cantonal level. The latter measure constitutes the explained variable
in the econometric model defined by equation (2).
Since many explanatory variables were available for 2002 only, we esti-
mated equation (2) using four quarters. As an exception, the level of educa-
tion (EDU) refers to year 2000. Table 2 gives summary statistics of variables
included in the model.
Variables Unit of measurement Min. Med. Max.
Per capita outpatient Defined Daily Doses 4.4 8.2 19.3
antibiotic consumption (DID)
Income per capita (Y) CHF/inhabitant 35952 45746 77583
Physicians’ density (Dph) Physicians/100’000 118 160 353
Pharmacies’ density (Dpha) Pharmacies/100’000 5 18 55
Population age over 65 (over65) Over 65/pop. 0.12 0.15 0.21
Population age under 20 (under20) Under 20/pop. 0.17 0.24 0.26
Share of foreign population (FO) Foreign people/pop. 0.09 0.19 0.38
Percentage of people without Basic education/pop. 0.19 0.24 0.32
post-mandatory education
Table 2: Variables notation and summary statistics
3.3 Estimation results
The estimation of the ad-hoc demand equation specified by (2) gives satis-
factory and stable results. We summarize them in table 3, both for the OLS
and the GLS methods.
In both models the majority of the coeﬃcients are significantly diﬀerent
from zero and carry the expected sign. Moreover, diﬀerences in coeﬃcients
between the two models are relatively small. The adjusted R-squared in
the OLS estimation suggests that the model explains around 87% of total
variations.
Since per capita antibiotic consumption and regressors are in logarithm
form, the coeﬃcients can be interpreted as health expenditure elasticities.
For instance, the income elasticity of health expenditure is negative and
significantly diﬀerent from zero. This result entails that income have a sig-
nificant influence on the level of per capita antibiotic consumption. Similarly
for education, the coeﬃcient shows that an increase in the percentage of
people without post-mandatory education increases the per capita antibiotic
consumption. The impact of income and education confirm that income is
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highly correlated with the level of education: the higher the level of income
and education, the lower the per capita consumption of antibiotics.
In terms of the investment in health function in the Grossman model
the results suggest that relatively rich and highly educated people either use
health care inputs (antibiotics) more eﬃciently or have higher initial health
stocks. Higher levels of productivity imply that the same amount of health
investment can be obtained by a lower amount of health care services. Also,
higher initial health stocks imply that lower investment in health, and hence
in health care inputs, are required for any given level of optimal health stocks,
ceteris paribus.
Elasticities of physicians’ density show positive values. This implies that
an increase in the number of physicians at cantonal level causes an increase in
the cantonal per capita antibiotic consumption. A 10% increase in physicians’
density increases per capita daily doses approximately by 9%.
The result suggests some evidence of supply-induced demand in the Swiss
health care sector. This is in accordance with the literature suggesting that
systems where physicians are paid under a fee-for-service scheme,10 akin to
the Swiss one overconsumption of drugs is more likely. On the other side,
the coeﬃcient on the density of pharmacies is not significant. The rationale
may be that antibiotics can only be bought under physician’s prescription.
Elderly people are less likely to use antibiotics compared to other cat-
egories. This is suggested by the negative coeﬃcient of the percentage of
population aged over 65. The reason may be found in the fact that elderly
people living at home, and not in nursing homes, experience a low incidence
of illness. On the other side, the percentage of population aged under 20 has
a positive impact on consumption but this is not significant.
With respect to the share of foreign people on the total population, a 1%
increase is associated to 0.17% increase in the per capita outpatient antibiotic
consumption. Cultural diﬀerences or diﬀerences in the incidence of infectious
diseases may account for this result.
Time dummies suggest that there are some seasonal eﬀects in antibiotic
consumption in ambulatory care. The coeﬃcient of the winter dummy, β11,
is positive and significatly diﬀerent from zero. On the other side, spring and
summer dummies are negative and significant. Hence, the hypothesis that
cantonal consumption is indeed higher in winter periods and lower in spring
and summer periods compared to autumn periods could not be rejected. This
may capture the seasonal trend in the incidence of respiratory tract infections
which aﬀects the use of antibiotics in ambulatory care.
10For further details on the supplier induced demand theory see McGuire (2000).
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OLS GLS
Coeﬃcients Standard Errors Coeﬃcients Standard Errors
Constant 0.498 1.973 −0.807 1.692
ln Y −0.527∗∗ 0.190 −0.527∗∗∗ 0.078
ln P −0.253 0.160 −0.341 0.252
ln Dph 0.026∗∗∗ 0.078 0.918∗∗∗ 0.094
ln Dpha 0.026 0.032 0.024∗∗∗ 0.003
ln under20 0.302 0.370 0.089 0.222
ln over65 −0.796∗∗ 0.286 −0.984∗∗∗ 0.241
ln FO 0.193∗∗ 0.066 0.173∗∗∗ 0.049
ln EDU 0.692∗∗∗ 0.174 0.831∗∗∗ 0.211
ln INF1 0.062∗∗ 0.022 0.078∗∗∗ 0.008
ln INF2 −0.037 0.028 −0.039∗∗∗ 0.006
DT1 0.077∗∗∗ 0.008 0.073∗∗∗ 0.004
DT2 −0.197∗∗∗ 0.008 −0.202∗∗∗ 0.004
DT3 −0.178∗∗∗ 0.006 −0.173∗∗∗ 0.005
* signifi cant at 5% , ** signifi cant at 1% , *** signifi cant at 0.1% .
Table 3: Estimated coeﬃcients obtained by OLS and GLS methods.
4 Conclusions
The investigation of regional variations in outpatient antibiotic consumption
may help to understand the determinants of the demand for antibiotics and
contribute to the discussion on the reduction of antibiotic resistance. There
is a lack of empirical evidence both in the analysis of within country and
within country variations in antibiotic consumption.
We investigated outpatient antibiotic consumption in Switzerland at can-
tonal level and by comparison with other European countries. We showed
that Switzerland uses relatively low volumes of antibiotics in ambulatory
care. In terms of consumption structure, Switzerland is characterized by
higher proportions of Quinolones.
Antibiotic consumption in ambulatory care has significantly increased
in terms of Defined Daily Doses per 1000 inhabitants per day (DID) and
sales per capita between 2002 and 2003 in most Swiss cantons. This is in
accordance with time trends in other European countries.
The investigation of cantonal diﬀerences led to wide variations between
cantons. Variations are less remarkable in terms of consumption structure.
Regional variations in antibiotic use within the country can hardly be
explained by epidemiological reasons. Multiple regressions on quarterly data
for 2002 using OLS and GLS estimators suggested that demographic fac-
tors, density of pharmacies and doctors, income and price may contribute to
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explain cantonal diﬀerences in antibiotic use.
Our findings may suggest the direction of more eﬀective policies to im-
prove the eﬃcient use of antibiotics in the community. Incentives aﬀecting
the impact of crucial determinants of antibiotic consumption should be de-
signed to obtain more appropriate consumption and resistance levels.
Econometric models using data at local level and the application of multi-
ple-choice models to selected categories of antibiotics are required to confirm
previous findings and capture the eﬀects of seasonal consumption patterns
and additional determinats of local diﬀerences, including endogenous bacte-
rial resistance.
References
Becker GS. “A Theory of the Allocation of Time”, Economic Journal, 75, S, 493-
517, 1965.
Belongia EA, and Schwartz B. “Strategies for promoting judicious use of antibiotics
by doctors and patients”, BMJ, 317, 668-671, 1998.
Bergan T. “Antibiotic usage in Nordic countries”, International Journal of An-
timicrobial Agents, 2001.
Bremon AR, et al. “Non-hospital consumption of antibiotics in Spain: 1987-1997”,
Journal Antimicrobial Chemotherapy, 2000.
Butler CC, et al. “Understanding the culture of prescribing: qualitative study
of general practitioners’ and patients’ perceptions of antibiotics for sore throats”,
BMJ, 317, 637-642, 1998.
Cantrell R, Young AF, and Martin BC. “Antibiotic prescribing in ambulatory care
settings for adults with colds, upper respiratory tract infections, and bronchitis”,
Clinical Therapeutics, 24, 170-182, 2002.
Canadian Compuscript Audit and Statistics Canada, www.ccar-ccra.com/english/-
dateline-e.shtml, October 2003.
Cars O, Molstad S, and Melander A. “Variation in antibiotic use in the European
Union”, Lancet, 357, 1851-1853, 2001.
Cizman M. "The use and resistance to antibiotics in the community", International
Journal of Antimicrobial Agents, 21, 297-307, 2003.
Cockburn J, and Pit S. “Prescribing behaviour in clinical practice: patients’ expec-
tations and doctors’ perceptions of patients’ expectations - a questionnaire study”,
BMJ, 315, 520-5231997.
18
Coast J, Smith RD, and Millar MR. “An economic perspective on policy to reduce
antimicrobial resistance”, Social Science and Medicine, Vol 46, No1, 29-38, 1998.
Elbasha EH. “Deadweight loss of bacterial resistance due to overtreatment”, Health
Economics, 12, 125-138, 2003.
Elseviers M, Ferech M, Van der Stichele R, and Goossens H. Consumption of
antibiotics in ambulatory care in Europe", www.ua.ac.be/main.asp?c=*ESAC.,
2003.
Finch RG, Metlay JP, Davey PG, Baker LL. “Educational interventions to improve
antibiotic use in the community: report from the International Forum on antibiotic
resistance (IFAR) colloquium”, Lancet, 4, 44-53, 2004.
Greene WH. Econometric Analysis, New York: Prentice Hall, 2003.
Grossman M, "On the Concept of Health Capital and the Demand for Health,"
JPE, 80, 223-255, 1972.
Harbarth S, AlbrichW, and Brun-Buisson C. “Outpatient antibiotic use and preva-
lence of antibiotic-resistance pneumococci in France and Germany: a sociocultural
perspective”, Emerging Infectious Diseases, Vol 8, No 12, 2002.
Homer J, et al. “Toward a dynamic theory of antibiotic resistance”, System Dy-
namics Review, Vol. 16, 4, 287-319, 2000.
Scott T. “The economics of general practice”, in: AJ Culyer and JP Newhouse,
eds., Handbook of Health Economics, Vol. 1, Ch. 22, 2000.
Kmenta J. Elements of Econometrics, 2d edition. New York: Macmillan Publish-
ing Company, 1986.
Laxminarayan R, and Weitzman ML. “On the implications of endogenous resis-
tance to medications”, Journal of Health Economics, 21, 709-718, 2002.
Levy SB. "The challenge of antibiotic resitance", Scientific American, 46-53, 1998.
McCaig LF, Besser RE, and Hughes JM. “Antimicrobial drug prescriptions in
ambulatory care settings, Unites States, 1992-2000”, Emerging Infectious Diseases,
Vol 9, No 4, 432-437, 2003.
Mecfarlane J, et al. “Reducing antibiotic use for acute bronchitis in primary care:
blinded, randomised controlled trial of patient information leaflet”, BMJ, 315,
1211-1214, 2002.
McGowan JE. “Economic impact of antimicrobial resistance”, Emerging Infectious
Diseases, Vol 7, No 2, 286-292, 2001.
McGuire T. "Physician agency", in the Handbook of health economics, Volume1.
Chapter 9, 461-536, Ed. Elsevier Science. 2000.
19
Newhouse JP. Free for all? Lessons from the Rand Health Insurance Experiment
Group. Harward University press, Cambridge, 1993.
OCECD. OECD Health Data, 2003.
Roger WH. “Regression standard errors in clustered samples" ” , Stata Technical
Bulletin, 13: 19-23 (reprinted in emphStata Technical Bulletin Reprints, Vol.3,
88-94), 1993.
Rowthorn R, and Brown GM. "Using antibiotics when resistance is renewable” in
Laxminarayan R, Battling resistance to antibiotics and pesticides, 1994.
Rudholm N. “Economic implications of antibiotic resistance in global economy”,
Journal of Health Economics, 21, 1071-1083, 2002.
Steinman MA, Gonzales R, Linder JA, Landefeld CS. “Changing use of antibiotics
in community-based outpatient practice 1991-1999”, Annals of Internal Medicine,
Vol 138, N0 7, 525-534, 2003.
Unsworth L, and Walley T. “Trends in primary care antibiotics prescribing in
England 1994-1998”, Pharmacoepidemiology and Drug Safety, 10, 309-314, 2001.
Weeb S, Lloyd M. "Prescribing and referral in general practice: a study of patients’
expectation and doctors’ actions", Br J Gen Pract, 44, 165-169, 1992.
WHO, “Overcoming antimicrobial resistance ”,World Health Report on infectious
diseases, 2000.
WHO, The WHO Global Strategy for Containment of Antimicrobial Resistance,
2001.
Wise R, et al. "Antimicrobial resitance. Is a major threat to public health", BMJ,
317, 609-610, 1998.
20
 
 
 
QUADERNI DELLA FACOLTÀ 
 
 
 
I quaderni sono richiedibili (nell’edizione a stampa) alla Biblioteca universitaria di Lugano 
via G. Buffi 13  CH 6900 Lugano 
e-mail: biblioteca@lu.unisi.ch 
 
The working papers (printed version) may be obtained by contacting the Biblioteca universitaria di 
Lugano 
via G. Buffi 13  CH 6900 Lugano 
e-mail: biblioteca@lu.unisi.ch 
 
 
 
Quaderno n. 98-01 
P. Balestra, Efficient (and parsimonious) estimation of structural dynamic error 
component models 
 
Quaderno n. 99-01 
M. Filippini, Cost and scale efficiency in the nursing home sector : evidence from 
Switzerland  
 
Quaderno n. 99-02 
L. Bernardi, I sistemi tributari di oggi : da dove vengono e dove vanno 
 
Quaderno n. 99-03 
L.L. Pasinetti, Economic theory and technical progress 
 
Quaderno n. 99-04 
G. Barone -Adesi, K. Giannopoulos, L. Vosper, VaR without correlations for portfolios 
of derivative securities 
 
Quaderno n. 99-05 
G. Barone-Adesi, Y. Kim, Incomplete information and the closed-end fund discount  
 
Quaderno n. 99-06 
G. Barone -Adesi, W. Allegretto, E. Dinenis, G. Sorwar, Valuation of derivatives based 
on CKLS interest rate models 
 
Quaderno n. 99-07 
M. Filippini, R. Maggi, J. Mägerle , Skalenerträge und optimale Betriebsgrösse bei den 
schweizerische Privatbahnen 
 
Quaderno n. 99-08 
E. Ronchetti, F. Trojani, Robust inference with GMM estimators 
 
Quaderno n. 99-09 
G.P. Torricelli, I cambiamenti strutturali dello sviluppo urbano e regionale in Svizzera e 
nel Ticino sulla base dei dati dei censimenti federali delle aziende 1985, 1991 e 1995 
 
Quaderno n. 00-01 
E. Barone, G. Barone-Adesi, R. Masera, Requisiti patrimoniali, adeguatezza del 
capitale e gestione del rischio  
 
Quaderno n. 00-02 
G. Barone-Adesi, Does volatility pay? 
 
Quaderno n. 00-03 
G. Barone-Adesi, Y. Kim, Incomplete information and the closed-end fund discount 
 
Quaderno n. 00-04 
R. Ineichen, Dadi, astragali e gli inizi del calcolo delle probabilità  
 
Quaderno n. 00-05 
W. Allegretto, G. Barone-Adesi, E. Dinenis, Y. Lin, G. Sorwar, A new approach to 
check the free boundary of single factor interest rate put option 
 
Quaderno n. 00-06 
G.D.Marangoni,  The Leontief Model and Economic Theory 
 
Quaderno n. 00-07 
B. Antonioli, R, Fazioli, M. Filippini, Il servizio di igiene urbana italiano tra 
concorrenza e monopolio 
 
Quaderno n. 00-08 
L. Crivelli, M. Filippini, D. Lunati. Dimensione ottima degli ospedali in uno Stato 
federale 
 
Quaderno n. 00-09 
L. Buchli, M. Filippini, Estimating the benefits of low flow alleviation in rivers: the case 
of the Ticino River 
 
Quaderno n. 00-10 
L. Bernardi, Fiscalità pubblica centralizzata e federale: aspetti generali e il caso 
italiano attuale 
 
Quaderno n. 00-11 
M. Alderighi, R. Maggi, Adoption and use of new information technology 
 
Quaderno n. 00-12 
F. Rossera, The use of log-linear models in transport economics: the problem of 
commuters’ choice of mode 
 
Quaderno n. 01-01 
M. Filippini, P. Prioni, The influence of ownership on the cost of bus service provision 
in Switzerland. An empirical illustration  
 
Quaderno n. 01-02 
B. Antonioli, M. Filippini, Optimal size in the waste collection sector 
 
Quaderno n. 01-03 
B. Schmitt, La double charge du service de la dette extérieure 
 
Quaderno n. 01-04 
L. Crivelli, M. Filippini, D. Lunati, Regulation, ownership and efficiency in the Swiss 
nursing home industry 
 
Quaderno n. 01-05 
S. Banfi, L. Buchli, M. Filippini, Il valore ricreativo del fiume Ticino per i pescatori 
 
Quaderno n. 01-06 
L. Crivelli, M. Filippini, D. Lunati, Effizienz der Pflegeheime in der Schweiz 
 
Quaderno n. 02-01 
B. Antonioli, M. Filippini, The use of a variable cost function in the regulation of the 
Italian water industry 
 
Quaderno n. 02-02 
B. Antonioli, S. Banfi, M. Filippini, La deregolamentazione del mercato elettrico 
svizzero e implicazioni a breve termine per l’industria idroelettrica 
 
Quaderno n. 02-03 
M. Filippini, J. Wild, M. Kuenzle, Using stochastic frontier analysis for the access 
price regulation of electricity networks 
 
Quaderno n. 02-04 
G. Cassese, On the structure of finitely additive martingales 
 
Quaderno n. 03-01 
M. Filippini, M. Kuenzle, Analisi dell’efficienza di costo delle compagnie di bus italiane 
e svizzere 
 
Quaderno n. 03-02 
C. Cambini, M. Filippini, Competitive tendering and optimal size in the regional bus 
transportation industry 
 
Quaderno n. 03-03 
L. Crivelli, M. Filippini, Federalismo e sistema sanitario svizzero 
 
Quaderno n. 03-04 
L. Crivelli, M. Filippini, I. Mosca, Federalismo e spesa sanitaria regionale : analisi 
empirica per i Cantoni svizzeri 
 
Quaderno n. 03-05 
M. Farsi, M. Filippini, Regulation and measuring cost efficiency with panel data models 
: application to electricity distribution utilities 
 
Quaderno n. 03-06 
M. Farsi, M. Filippini, An empirical analysis of cost efficiency in non-profit and public 
nursing homes 
 
Quaderno n. 03-07 
F. Rossera, La distribuzione dei redditi e la loro imposizione fiscale : analisi dei dati 
fiscali svizzeri 
 
Quaderno n. 03-08 
L. Crivelli, G. Domenighetti, M. Filippini, Federalism versus social citizenship : 
investigating the preference for equity in health care 
 
Quaderno n. 03-09 
M. Farsi, Changes in hospital quality after conversion in ownership status 
 
Quaderno n. 03-10 
G. Cozzi, O. Tarola, Mergers, innovations, and inequality 
 
Quaderno n. 03-11 
M. Farsi, M. Filippini, M. Kuenzle , Unobserved heterogeneity in stochastic cost 
frontier models : a comparative analysis 
 
Quaderno n. 04-01 
G. Cassese, An extension of conditional expectation to finitely additive measures 
 
Quaderno n. 04-02 
S. Demichelis, O. Tarola, The plant size problem and monopoly pricing 
 
Quaderno n. 04-03 
F. Rossera, Struttura dei salari 2000 : valutazioni in base all’inchiesta dell’Ufficio 
federale di statistica in Ticino 
 
Quaderno n. 04-04 
M. Filippini, M. Zola, Economies of scale and cost efficiency in the postal services : 
empirical evidence from Switzerland 
 
Quaderno n. 04-05 
F. Degeorge, F. Derrien, K.L. Womack, Quid pro quo in IPOs : why book -building is 
dominating auctions 
 
Quaderno n. 04-06 
M. Farsi, M. Filippini, W. Greene , Efficiency measurement in network industries : 
application to the Swiss railway companies 
 
Quaderno n. 04-07 
L. Crivelli, M. Filippini, I. Mosca, Federalism and regional health care expenditures : 
an empirical analysis for the Swiss cantons 
 
Quaderno n. 04-08 
S. Alberton, O. Gonzalez, Monitoring a trans-border labour market in view of 
liberalization : the case of Ticino 
 
Quaderno n. 04-09 
M. Filippini, G. Masiero, K. Moschetti, Regional differences in outpatient antibiotic 
consumption in Switzerland 
 
 
 
